The blockbuster weight loss drug Ozempic – and its higher-dose counterpart Wegovy – is poised to become dramatically more accessible as generic versions hit the market in several of the world’s most populous nations. Starting this weekend, India will lead the charge, with China, Canada, Brazil, Turkey, and South Africa following in the coming months. This shift will significantly lower the price of a medication previously out of reach for all but the wealthiest individuals.
Patent Expiration and Global Impact
Novo Nordisk, the original manufacturer, is losing patent protection in countries representing 40% of the world’s population. This expiration marks a pivotal moment in global healthcare, as generics will flood markets with an estimated 800 million obese or overweight adults in India and China alone, plus over 360 million people living with diabetes.
The move promises to “democratize” access to a drug that has been largely restricted to high-income countries, according to Leena Menghaney, a treatment access activist in New Delhi. The current limited availability has stifled broader adoption despite the drug’s proven efficacy in treating obesity, preventing heart attacks, and reducing the risk of stroke.
Market Disruption and Future Outlook
Novo Nordisk and Eli Lilly have dominated sales in the limited markets where the drug has been available, but the entrance of generics will shake up this established system. Increased competition is expected to drive down prices, enabling a far wider patient base to benefit.
Notably, the United States and Europe won’t see generic Ozempic until the early 2030s, owing to regulatory protections designed to reward innovation by extending brand-name monopolies. This delay ensures continued high prices in those regions for the foreseeable future.
The global rollout of Ozempic generics represents a landmark shift in pharmaceutical access, with far-reaching implications for public health and the obesity treatment landscape.
